Anders Karlen
Overview
Explore the profile of Anders Karlen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
84
Citations
1361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fernow J, Olliver M, Couet W, Lagrange S, Lamers M, Olesen O, et al.
Nat Rev Drug Discov
. 2024 Sep;
24(1):1-2.
PMID: 39313598
No abstract available.
2.
Benediktsdottir A, Sooriyaarachchi S, Cao S, Ottosson N, Lindstrom S, Lundgren B, et al.
Eur J Med Chem
. 2024 Sep;
278:116790.
PMID: 39236497
New antibacterial compounds are urgently needed, especially for infections caused by the top-priority Gram-negative bacteria that are increasingly difficult to treat. Lipid A is a key component of the Gram-negative...
3.
Huseby D, Cao S, Zamaratski E, Sooriyaarachchi S, Ahmad S, Bergfors T, et al.
Proc Natl Acad Sci U S A
. 2024 Apr;
121(15):e2317274121.
PMID: 38579010
Here, we describe the identification of an antibiotic class acting via LpxH, a clinically unexploited target in lipopolysaccharide synthesis. The lipopolysaccharide synthesis pathway is essential in most Gram-negative bacteria and...
4.
Miethke M, Pieroni M, Weber T, Bronstrup M, Hammann P, Halby L, et al.
Nat Rev Chem
. 2023 Apr;
5(10):726-749.
PMID: 37118182
An ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in...
5.
Grinkevich V, Vema A, Fawkner K, Issaeva N, Andreotti V, Dickinson E, et al.
Front Mol Biosci
. 2022 Jun;
9:823195.
PMID: 35720128
Restoration of the p53 tumor suppressor for personalised cancer therapy is a promising treatment strategy. However, several high-affinity MDM2 inhibitors have shown substantial side effects in clinical trials. Thus, elucidation...
6.
Szalaj N, Benediktsdottir A, Rusin D, Karlen A, Mowbray S, Wieckowska A
Eur J Med Chem
. 2022 Jun;
238:114490.
PMID: 35660251
The ever-increasing number of bacteria resistant to the currently available antibacterial agents is a great medical problem today, and new antibiotics with novel mechanisms of action are urgently needed. Among...
7.
Lu L, Akerbladh L, Ahmad S, Konda V, Cao S, Vocat A, et al.
ACS Infect Dis
. 2022 Feb;
8(3):482-498.
PMID: 35184552
Type II NADH dehydrogenase (NDH-2) is an essential component of electron transfer in many microbial pathogens but has remained largely unexplored as a potential drug target. Previously, quinolinyl pyrimidines were...
8.
Olanders G, Brandt P, Skold C, Karlen A
Bioorg Med Chem
. 2021 Oct;
49:116399.
PMID: 34601455
Macrocycles form an important compound class in medicinal chemistry due to their interesting structural and biological properties. To help design macrocycles, it is important to understand how the conformational preferences...
9.
Miethke M, Pieroni M, Weber T, Bronstrup M, Hammann P, Halby L, et al.
Nat Rev Chem
. 2021 Aug;
5(10):726-749.
PMID: 34426795
An ever-increasing demand for novel antimicrobials to treat life-threatening infections caused by the global spread of multidrug-resistant bacterial pathogens stands in stark contrast to the current level of investment in...
10.
Benediktsdottir A, Lu L, Cao S, Zamaratski E, Karlen A, Mowbray S, et al.
Eur J Med Chem
. 2021 Aug;
224:113699.
PMID: 34352713
Oligopeptide boronates with a lipophilic tail are known to inhibit the type I signal peptidase in E. coli, which is a promising drug target for developing novel antibiotics. Antibacterial activity...